Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Rett Syndrome Clinical Trial

Official title:

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02153723
• Other study ID #: 13-05-117
• Status: Completed
• Phase: Phase 2
• Start date: August 2013
• Est. completion date: January 2016

Study information

• Verified date: October 2018
• Source: Montefiore Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase 2 open label trial to test a potential drug treatment for Rett syndrome, the leading known genetic cause of severe neurological impairment in girls. The drug, Copaxone (generic name - Glatiramer acetate) is medication FDA approved for the treatment of multiple sclerosis. Copaxone's high safety profile has been documented in large cohorts of patients for more than 12 years.

Description:

Background/rationale for the study:

In Rett syndrome brain cells aren't actually lost, instead poor maturation of connections between brain cells (synapses) prevents effective neurological functioning, and is the main morphological feature of the disease. The MeCP2 gene plays a major role in transcriptional regulation of other genes, one of which is the gene encoding brain-derived neurotrophic factor (BDNF).

The disease progression and severity of symptoms is directly affected by the level of BDNF expression. An increase of BDNF levels (by genetic manipulations or pharmacological agents) leads to delayed onset of Rett syndrome-like symptoms in experimental models; rescued gait/mobility, improved quality of life and increased survival rates.

Copaxone treatment by subcutaneous injection caused elevation of BDNF levels. Quantitative immunofluorescence assays showed about a twofold increase in neuronal expression of BDNF following Copaxone treatment.

We expect that an increase in BDNF levels with Copaxone administration will stimulate communication between brain cells (synaptic maturation), which will lead to amelioration of symptoms (motor functions/gait, cognitive functions, breathing, encephalopathy and improve quality of life) for girls with Rett syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: January 2016
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

• Female patients with genetically confirmed Rett Syndrome (RTT)

• Age: 10 or more years old. Selection of the age is based on the available evidence of the safety of Glatiramer Acetate (GA) in this group, and the relative homogeneity/stability of the phenotype, which is not expected to spontaneously change within a 6 month period at this age

• Ambulatory (with our without support)

Exclusion Criteria:

• Prolonged Qtc (obtained within 30 days prior to enrollment)

• Presence of co morbid non-Rett related disease

• Presence of immunodeficiency requiring intravenous immunoglobulin 3 (IVIG 3) months prior to enrollment

• Allergy/sensitivity to GA or mannitol

• Inability or unwillingness of legal guardians to give written informed consent

Related Conditions & MeSH terms

• Rett Syndrome
• Syndrome

Intervention

Drug:
• Glatiramer Acetate

Locations

Country	Name	City	State
United States	Montefiore Medical center	Bronx	New York

Sponsors (2)

Lead Sponsor	Collaborator
Montefiore Medical Center	Rett Syndrome Research Trust

Country where clinical trial is conducted

United States, 

References & Publications (1)

Djukic A, Holtzer R, Shinnar S, Muzumdar H, Rose SA, Mowrey W, Galanopoulou AS, Shinnar R, Jankowski JJ, Feldman JF, Pillai S, Moshé SL. Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. Pediatr Neurol. 2016 Aug;61:51-7. doi: 10.1016/j.ped — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gait Velocity as Measured by GAITRite System	To perform quantitative gait assessments a computerized walkway (457 × 90.2 × 0.64cm) with embedded pressure sensors (GAIT Rite system) was used. Subjects walked on the walkway for two trials, while wearing comfortable footwear.	Baseline and Final week of treatment (week 32)
Secondary	Breath Hold Index (Number of Breath Holds Per Hour; Assessed in the Sleep Monitoring Lab)	Breath hold index is defined as number of breath holds/hour. Respirations were monitored with sleep monitoring equipment during the daytime at the polysomnography laboratory with additional oronasal airflow, electromyography (EMG), EEG and video monitoring to confirm wakefulness during the period of study.	Baseline and during final week of treatment (week 32)
Secondary	Breath Hold Time (Assessed in the Sleep Monitoring Lab)	Breath Hold Time is defined as percentage of time spent holding the breath in a specific time unit. It is measured by a standard medical technique where belts are placed on the chest and abdomen to record movement and sensors are used to record nasal flow. Wake respiration was monitored with sleep monitoring equipment during the daytime at the polysomnography laboratory with additional oronasal airflow, EMG, EEG and video monitoring to confirm wakefulness during the period of study.	Baseline and Final week of treatment (week 32)
Secondary	Visual Memory Novelty Score as Assessed by TX300 Tobii Computer.	Eye-tracking is considered an indication of visual memory. Eye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 computer (Tobii Technology, Danderyd, Sweden). The actual data given by the computer represents the percentage of time spent looking at a novel visual target - this is called the novelty score. Visual memory, as indexed by the novelty score, is the percentage of time spent looking at a novel target during the test ("visual paired comparison paradigm"). Duration of testing was 2 minutes.	Baseline and Final week of treatment (week 32)
Secondary	Visual Attention (Number of Fixations) Assessed by Eye-tracking TX300 Tobii Computer.	Visual attention is indexed by duration and number of fixations on novel target on testing. The standard method of assessing visual attention in neuropsychology is by measuring: A)number of fixations (how many times the subject looks at each of the 2 visual targets). The higher number of fixations, the more attentive the subject to that visual target.; B) duration of fixations in seconds (the longer the fixation the more attentive). Duration of fixations correlates with intelligence: the smarter the person is the shorter his fixations are.; Eye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 (Tobii Technology AB, Danderyd, Sweden). The measured index is called the Novelty Score which indicates the percentage of time spent looking at novel visual target. Duration of testing session was 2 minutes.	Baseline and Final week of treatment (week 32)
Secondary	Visual Attention (Fixation Length) Assessed by Eye-tracking TX300 Tobii Computer.	The standard method of assessing visual attention in neuropsychology is by measuring: A)number of fixations (how many times the subject looks at each of the 2 visual targets). The higher number of fixations, the more attentive the subject to that visual target.; B) duration of fixations in seconds (the longer the fixation the more attentive). Duration of fixations correlates with intelligence: the smarter the person is the shorter his fixations are.; Eye-tracking data was recorded at 300 Hz sampling rate using a Tobii T300 (Tobii Technology AB, Danderyd, Sweden). The measured index is called the Novelty Score which indicates the percentage of time spent looking at novel visual target. Visual attention is indexed by number of fixations on novel target on test.; Duration of testing session was 2 minutes.	Baseline and Final week of treatment (week 32)